SLC5A2 and type 2 diabetes mellitus: A recent meta-analysis of 130 RCTs screening SGLT2-i safety in elderly T2DM subjects (including 19,986 patients) did not show any difference in the euDKA risk between the SGLT2-i and placebo groups [60].